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Background: Anakinra (ANA) is an effective treatment choice in patients with adult
onset Still’s disease (AOSD). Variables affecting treatment survival include loss of efficacy
or adverse events, but also the decision to discontinue treatment after long-term
clinical remission.
Objectives: Aims of this study were: (i) to assess the drug retention rate (DRR) of ANA
during a long-term follow-up looking for any difference related to the line of biologic
treatment, the concomitant use of conventional disease modifying anti-rheumatic drugs
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(cDMARDs) and the different type of AOSD (systemic versus chronic articular); (ii) to
identify predictive factors of lack of efficacy, loss of efficacy, and ANA withdrawal owing
to long-term remission.
Methods: AOSD patients classified according with Yamaguchi criteria and treated with
ANA were retrospectively enrolled in 18 Italian tertiary Centers. Demographic, laboratory,
clinical and therapeutic data related to the start of ANA (baseline), the 3-month
assessment and the last follow-up visit while on ANA treatment were retrospectively
collected and statistically analyzed.
Results: One hundred and forty-one AOSD patients (48 males, 93 females) treated
with ANA for a mean period of 35.96 ± 36.05 months were enrolled. The overall DRR
of ANA was 44.6 and 30.5% at the 60- and 120-month assessments, respectively,
with no significant differences between: (i) biologic naïve patients and those previously
treated with other biologics (log-rank p = 0.97); (ii) monotherapy and concomitant use of
cDMARDs (log-rank p = 0.45); (iii) systemic and chronic articular types of AOSD (log-rank
p = 0.67). No variables collected at baseline could predict primary inefficacy, while
the number of swollen joints at baseline was significantly associated with secondary
inefficacy (p = 0.01, OR = 1.194, C.I. 1.043–1.367). The typical AOSD skin rash
was negatively related with ANA withdrawal owing to long-term remission (p = 0.03,
OR = 0.224, C.I. 0.058–0.863).
Conclusion: Long-term DRR of ANA has been found excellent and is not affected by
different lines of biologic treatment, concomitant use of cDMARDs, or type of AOSD.
The risk of losing ANA efficacy increases along with the number of swollen joints at the
start of therapy, while the typical skin rash is a negative predictor of ANA withdrawal
related to sustained remission.
Keywords: autoinflammatory diseases, systemic onset juvenile idiopathic arthritis, personalized medicine,
canakinumab, innovative biotechnologies, interleukin-1
INTRODUCTION
Adult onset Still’s disease (AOSD) is a systemic inflammatory
disorder characterized by daily high-spiking fevers, evanescent
salmon-colored maculopapular rash, sore throat, serositis,
hepatosplenomegaly, lymphadenopathy, myalgia, arthritis,
and/or arthralgia. Laboratory investigations usually reveal
leukocytosis with neutrophil predominance, increased
acute-phase reactants and high levels of serum ferritin,
while serum liver enzymes may be often elevated (Pouchot
et al., 1991). This condition is frequently considered
as the adult counterpart of systemic onset juvenile
idiopathic arthritis (SOJIA) (Uppal et al., 1995; Luthi et al.,
2002; Martini, 2012).
Abbreviations: ANA, anakinra; AOSD, adult onset Still’s disease; cDMARDs,
conventional disease modifying anti-rheumatic drugs; CI, confidence interval;
CRP, C-reactive protein; CT, computed tomography; DAS28-CRP, disease activity
score in 28 Joints-C-reactive protein; DRR, drug retention rate; ESR, eritrocyte
sedimentation rate; IL, interleukin; IVIGs, intravenous immunoglobulins;
MAS, macrophage activation syndrome; MRI, magnetic resonance imaging;
NSAIDs, non-steroidal anti-inflammatory drugs; SOJIA, systemic onset juvenile
idiopathic arthritis.
Clinical presentation of AOSD can be distinguished into
two main phenotypes: a “systemic type” characterized by
predominantly systemic features including fever, rash,
serositis, and organomegaly, and a “chronic articular
type” with patients suffering from articular manifestations
mimicking rheumatoid arthritis with a polyarticular
symmetric pattern. The systemic type can be distinguished
into a monocyclic and polycyclic course. A monocyclic
AOSD is defined as a single flare lasting from 2 months to
1 year; conversely, the polycyclic course is characterized by
recurrent systemic flares with remissions between attacks
(Cush et al., 1987).
In the absence of a definitive diagnostic test, diagnosis
of AOSD is clinical and requires the exclusion of infectious,
neoplastic, autoimmune and other autoinflammatory diseases.
Different classification criteria have been proposed for AOSD
during the last decades, with the Yamaguchi’s criteria being
the most sensitive and the Fautrel’s Criteria the most specific
(Yamaguchi et al., 1992; Fautrel et al., 2002). However,
Fautrel’s set of criteria includes measurement of glycosylated
ferritin, which is not routinely available in many health
care facilities.
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Disease severity is often determined by using the Pouchot’s
score modified by Rau et al. (Pouchot et al., 1991; Rau
et al., 2010). This score ranges from 0 to 12 according to the
presence or absence of 12 AOSD-related manifestations, each
scoring one point.
The pathogenesis of AOSD is already widely unclear with
both innate and acquired immunity involved. Nevertheless,
based on clinical features and laboratory evidence, this disease
has been recently included among polygenic multifactorial
autoinflammatory disorders (Hayem, 2009; Rossi-Semerano
and Koné-Paut, 2012; Rigante, 2017). In this regard, as
for monogenic autoinflammatory diseases, interleukin(IL)-1
blockade has proven to induce a dramatic response in AOSD
patients with clinical and laboratory manifestations disappearing
within a few days from the start of treatment (Nordström
et al., 2008; Giampietro et al., 2013; Cavalli et al., 2015;
Ortiz-Sanjuán et al., 2015). On this basis, the IL-1β inhibitor
canakinumab has been approved for the treatment of AOSD
previously unresponsive to non-steroidal anti-inflammatory
drugs (NSAIDs) and corticosteroids. However, most of data
on the therapeutic role of IL-1 inhibition in AOSD patients
currently relates to the recombinant IL-1 receptor antagonist
Anakinra (ANA), associated or not with conventional disease
modifying anti-rheumatic drugs (cDMARDs). Sustained and
complete efficacy of ANA may also allow a decrease in the
frequency of injections until complete withdrawal in some cases
(Kong et al., 2010). Nevertheless, beyond the dramatic efficacy
reported in most patients, lack and loss of efficacy to ANA have
been frequently described (Giampietro et al., 2013; Ortiz-Sanjuán
et al., 2015; Rossi-Semerano et al., 2015). Hence, the present study
is aimed at assessing the long-term drug retention rate (DRR) of
ANA, taking into account the impact of lack and loss of efficacy,
adverse events and withdrawal owing to treatment-induced long-
term remission. In addition, predictive factors related to lack or
loss of efficacy or withdrawal because of long-term remission will
be sought among demographic, clinical and laboratory features
collected at the start of ANA treatment.
MATERIALS AND METHODS
Patients and Data Collection
Patients enrolled in the present study are almost overlapping
with those previously presented in a recent observational study
aimed at providing information about efficacy and safety of
ANA and Canakinumab when administered in AOSD patients
(Colafrancesco et al., 2017).
Demographic, clinical and laboratory data were
retrospectively collected from patients suffering from AOSD
treated with ANA and attending 18 Italian tertiary Centers.
All patients were diagnosed with AOSD according to the
Yamaguchi’s criteria (Yamaguchi et al., 1992).
Before starting ANA, patients had undergone a careful
laboratory and radiologic screening in order to rule out
infections, neoplasms, and other rheumatologic disorders.
Patients were closely monitored with weekly clinical and
laboratory evaluations during the first month of treatment and
then every 3 months or in case of clinical need (disease relapse or
safety concerns).
The primary aims of the study were: (i) to assess the long-term
DRR of ANA; (ii) to identify any demographic or clinical variable
capable to predict the lack or the loss of efficacy to ANA
treatment; (iii) to search for predictors of treatment withdrawal
owing to sustained remission while on ANA administration.
Secondary aims of the study were: (i) to identify any impact on
the DRR of ANA by the concomitant use of cDMARDs on the
DRR of ANA and by the different biologic line of ANA therapy;
(ii) to assess any difference on ANA retention rate according
with the different type (systemic versus chronic articular) of
AOSD; (iii) to evaluate the long-term cumulative risk for loss of
ANA efficacy; (iv) to assess variables related with the treatment
duration of ANA; (v) to clarify which AOSD manifestations are
more frequently persistent in patients suspending ANA because
of lack of efficacy.
The primary endpoints were represented by: (i) the
Kaplan–Meier survival estimates obtained during a 120-month
follow-up period; (ii) clinical and laboratory variables
significantly associated with lack of efficacy, loss of efficacy
and ANA withdrawal due to long-term AOSD remission at
regression analysis. Secondary endpoints were represented by
statistically significant differences in the Kaplan–Meier survival
curves between patients treated with ANA as first biologic
agent and those previously treated with other biologics; patients
concomitantly treated with cDMARDs and those undergoing
ANA as monotherapy; patients with systemic AOSD and patients
presenting chronic articular disease. Additional secondary
endpoints were represented by: the estimates of cumulative
probability of loss of ANA efficacy at the reverse Kaplan–Meier
analysis; the identification of clinical and laboratory AOSD
manifestations significantly more frequent at the 3-month
assessment (or at the last ANA administration) in subjects
experiencing lack of efficacy compared to the other patients; a
statistically significant correlation between treatment duration
and the following variables recorded at the start of ANA
treatment (baseline): age at disease onset, disease duration at
the start of ANA, Pouchot score, disease activity score in 28
Joints-C reactive protein (DAS28-CRP), serum ferritin level, and
physician’s global assessment.
The demographic, clinical and laboratory variables collected
at baseline and at the 3-month assessment were: age at
AOSD onset, age at diagnosis, disease duration at the start of
ANA treatment, number of tender joints, number of swollen
joints, DAS28-CRP, previous cDMARDs, previous biologics,
concomitant cDMARDs, concomitant corticosteroids, Pouchot
score, serum ferritin level, physician’s global assessment of
disease activity on a visual analog scale. In addition, the presence
or absence of the following clinical and laboratory manifestations
were collected: fever, salmon-colored maculopapular skin
rash, pleuritis, pneumonia, pericarditis, lymphadenopathy,
pharyngodynia, myalgia, arthritis, hepatomegaly, macrophage
activation syndrome (MAS), increased liver enzymes levels,
leukocytosis, increased erythrocyte sedimentation rate (ESR) and
raised CRP. At the last follow-up visit, treatment duration and
specific causes leading to ANA withdrawal (primary inefficacy,
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secondary inefficacy, long-term AOSD remission, safety issues,
and loss of compliance) were recorded.
The study protocol was conformed to the tenets of the
Declaration of Helsinki and was approved by the local
Ethics Committee of the University of Florence (Reference
No. 364-16OCT2013). Informed consent was obtained
from each patient.
Definition of Clinical and Laboratory
Criteria
The disease was considered “chronic articular” when involvement
was prevalently polyarticular with erosive damage and low
levels of inflammatory markers. Conversely, AOSD was
“systemic” if the patient showed increased inflammatory
markers, hyperferritinemia and multi-organ involvement.
Disease severity was determined using the modified Pouchot’s
score as proposed by Pouchot et al. (1991) and Rau et al. (2010).
Systemic AOSD was not distinguished into monocyclic and
polycyclic course, as this distinction has been found irrelevant
with respect to the prognostic stratification (Cush et al., 1987).
Fever was defined by a temperature higher than 39◦C.
Diagnosis of pleuritis, pericarditis and pneumonia was
based on echographic-radiological documentations; similarly,
lymphoadenopathy was confirmed by ultrasound and/or
computed tomography (CT) scan in at least two different
sites. Hepatomegaly was identified by ultrasound, CT scan or
magnetic resonance imaging (MRI). With regard to laboratory
evaluations, leukocytosis was defined as a white cell count
higher than 15,000/mm3 and hyperferritinemia consisted in
a serum ferritin level higher than 3,000 ng/ml; ESR and CRP
were considered elevated in accordance to each laboratory
reference limit.
A lack of efficacy (or primary inefficacy) was considered as
no satisfactory improvement of clinical manifestations during
the first weeks of ANA treatment according to physician’s
judgment. A loss of efficacy (or secondary inefficacy) was defined
as persistent reappearance of AOSD manifestations leading
to ANA withdrawal after a persistent complete response (at
least 3 months). Withdrawal of ANA owing to long-term
clinical remission was based on physician’s judgment; however, a
completely asymptomatic period of at least 6 months had been
observed in all cases discontinuing ANA due to persistent clinical
remission. Follow-up duration was defined as the time between
the start of ANA and time of ANA withdrawal or the last visit
while on ANA treatment.
The study was carried out in accordance with the tenets of
the Declaration of Helsinki and the recommendations of the local
Ethical Committee (AOUS, Siena, Italy) rules.
Statistical Analysis
Descriptive statistics included sample size, percentages, means,
and standard deviations. After having assessed normality
distribution with Shapiro–Wilk test, pair wise comparisons of
quantitative data were performed by using unpaired two-tailed
t-test or Mann–Whitney two tailed U-test, as appropriate; Fisher
exact test was used for analyzing categorical variables. Correlation
analysis was performed using the Spearman test and the Pearson
test, as required. Drug survival rates were analyzed by using
the Kaplan–Meier plot with “time 0” corresponding to the
start of treatment and the “event” being the discontinuation
of therapy. Log-rank (Mantel–Cox) test was used to compare
different survival curves. The cumulative risk for loss of efficacy
was assessed by reverse Kaplan–Meier plot with “time 0” being
the start of ANA and the “event” corresponding to treatment
withdrawal due to secondary inefficacy.
Binary regression analysis was performed using the
backward stepwise to identify baseline clinical and laboratory
features associated with lack of efficacy, secondary inefficacy
and long-term remission leading to ANA withdrawal as
dependent variables. The demographic, clinical and laboratory
data collected at baseline as listed above were used as
independent variables.
Binary regression analysis aimed at identifying variables
related to ANA withdrawal due to long-term remission
was performed on patients suffering from active AOSD for
at least 12 months in order to exclude subjects with a
monocyclic disease course.
Odds ratio (OR), its statistical significance and corresponding
95% CI were evaluated for independent variables significantly
associated with dependent variables at regression analysis.
The SPSS software, version 24, was used for all statistical
computations, always considering a significance level of 95%
(p-value < 0.05).
RESULTS
One hundred and forty-one patients (48 males, 93 females)
treated with ANA because of AOSD were enrolled in the
study. Their demographic and clinical data are summarized in
Table 1, while Table 2 provides information about previous and
concomitant treatments.
ANA was administered for a mean period of
35.96± 36.05 months (median period of 23 months). Withdrawal
of ANA was observed in 20 patients (14.2%) because of long-term
treatment-induced remission, 16 cases (11.3%) due to primary
inefficacy and in 11 (7.8%) cases because of secondary inefficacy.
Other 25 (17.7%) patients discontinued ANA because of side
effects, as reported in Table 3.
Seventeen out of 20 patients suspending ANA due to
long-term remission had suffered from active AOSD for at least
12 months. These patients were treated with ANA for a mean
period of 35.6 ± 35.4 months. All but two patients experiencing
primary inefficacy continued ANA up to the 3-month follow-up
visit; secondary inefficacy was observed after a mean period of
35.8 ± 36.1 months of treatment. Figure 1 shows the cumulative
risk for loss of efficacy over time, which was 3.4% during the
first 12 months, 13.5% at the 60-month assessment, and 17.5%
after 120 months.
Regarding dosages employed, 128 (90.8%) patients were
administered with standard posology (100 mg/day), 4 (2.8%)
patients with higher dosages (200 mg/day), and 9 (6.4%) with
lower than standard dosages (100 mg every other day or less).
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TABLE 1 | Demographic, clinical, and laboratory variables referred to the start of
Anakinra in the entire cohort of patients enrolled with AOSD.
Demographic features and disease patterns
Age at disease onset, years (mean ± SD) 35.3 ± 17.1
Age at diagnosis, years 37.32 ± 16.95
Disease duration before starting ANA, months 50.4 ± 81.6
Systemic disease pattern 105 (74.5%)
Chronic articular pattern 36 (25.5%)
Clinical manifestations, n (%)
Number of tender joints 6.6 ± 6.1
Number of swollen joints 3.0 ± 4.2
DAS28-CRP 4.5 ± 1.5
Pouchot score 5.58 ± 1.92
Body temperature ≥ 39◦C 136 (96.5)
Salmon-like skin rash 104 (73.8)
Pleuritis 21 (14.9)
Pericarditis 26 (18.4)
Pneumonia 10 (7.1)
Lymphoadenitis 73 (51.8)
Hepatomegaly 66 (46.8)
Pharingodynia 76 (53.9)
Arthritis 99 (70.2)
MAS during clinical history 12 (8.5)
Altered laboratory markers, n (%)
Increased ESR 120 (85.1)
Increased CRP 129 (91.5)
Leukocytosis 99 (70.2)
Increased serum ferritin 95 (67.4)
Increase liver enzymes 47 (33.3)
ANA, anakinra; CRP, C-reactive protein; DAS28-CRP, disease activity score in 28
Joints-C-reactive protein; ESR, erythrocyte sedimentation rate; MAS, macrophage
activation syndrome; SD, standard deviation.
The overall DRR of ANA was 44.6 and 30.5% at the 60- and
120-month assessments, respectively. After having excluded
patients suspending ANA due to long-term remission, the DRR of
ANA was 55.2 and 39.5% at the 60- and 120-month assessments,
respectively. After excluding also patients discontinuing ANA
because of adverse events, the DRR of ANA was 68.2 and 54.6% at
the 60- and 120-month evaluations, respectively. These data are
illustrated in Figure 2 as Kaplan–Meier survival curves during a
120-month follow-up period.
As represented in Figure 3, no differences were found in the
DRR of ANA between patients undergoing their first biologic
agent and those previously treated with other biologics (log-rank
p = 0.97). Similarly, no differences were highlighted in the
DRR of ANA between patients treated with IL-1 inhibition
as monotherapy and those co-administered with cDMARDs
both at baseline (log-rank p = 0.45) and at the last follow-up
(log-rank p = 0.28). These results are graphically represented
in Figure 4. The lack of statistical significance was maintained
when patients suspending ANA due to clinical remission were
excluded (log-rank p = 0.62 at baseline and log-rank p = 0.24
at the last follow-up). No statistically significant differences were
identified in the DRR of ANA between the systemic and the
chronic articular type (log-rank p = 0.67) of AOSD, as also
reported in Figure 5.
TABLE 2 | Information about treatment approaches preceding and accompanying
treatment with Anakinra (ANA).
Number of
patients (%)
Previous treatments
NSAIDs 97 (68.8)
Corticosteroids 138 (97.9)
cDMARDs 120 (85.1)
Methotrexate 91 (64.5)
Cyclosporine 50 (35.5)
Hydroxychloroquine 30 (21.3)
Colchicine 12 (8.5)
Azathioprine 9 (6.4)
Salazopyrine 8 (5.7)
Leflunomide 5 (3.5)
Gold salts 1 (0.7)
IVIGs 1 (0.7)
Biologic agents 29 (20.6)
Etanercept 20 (14.9)
Infliximab 10 (7.1)
Adalimumab 6 (4.3)
Golimumab 2 (1.4)
Tocilizumab 2 (1.4)
Abatacept 2 (1.4)
Rituximab 2 (1.4)
Certolizumab 1 (0.7)
Concomitant treatments at baseline
cDMARDs 87 (61.7)
Methotrexate 63 (44.7)
Cyclosporine 15 (10.6)
Hydroxychloroquine 12 (8.5)
Colchicine 4 (2.8)
Leflunomide 2 (1.4)
Salazopyrine 2 (1.4)
Corticosteroids at the last follow-up 58 (41.1)
cDMARDs at the last follow-up 72 (51.1)
cDMARDs, conventional disease modifying anti-rheumatic drugs; IVIGs,
intravenous immunoglobulins; NSAIDs, non-steroidal anti-inflammatory drugs.
TABLE 3 | Adverse events inducing Anakinra withdrawal during the whole
follow-up period.
Adverse events Frequency, n (%)
In-site reactions 10 (7.1)
Generalized urticarial rash 6 (6.3)
Leukopenia/decreased platelet count 2 (1.4)
Angioedema 2 (1.4)
Macrophage activation syndrome 2 (1.4)
Infections 1 (0.7)
Lymphoproliferative disorders 1 (0.7)
Eosinophilia 1 (0.7)
No significant correlations were identified between treatment
duration and age at disease onset (ρ = −0.11, p = 0.24), disease
duration at the start of ANA (ρ = 0.10, p = 0.31), baseline Pouchot
score (ρ = 0.03, p = 0.77), DAS28-CRP (ρ = 0.06, p = 0.56),
Frontiers in Pharmacology | www.frontiersin.org 5 April 2019 | Volume 10 | Article 296
fphar-10-00296 April 2, 2019 Time: 11:28 # 6
Vitale et al. Anakinra Effectiveness in AOSD
FIGURE 1 | Reverse Kaplan–Meier survival curve showing the cumulative risk
for loss of efficacy to Anakinra treatment over time. The “time 0” is
represented by the start of ANA treatment; the “event” corresponds to
treatment withdrawal due to secondary inefficacy.
FIGURE 2 | Kaplan–Meier survival curves describing the cumulative retention
of Anakinra over the whole follow-up period taking into account all causes of
treatment withdrawal (blue line), only adverse events and lack/loss of efficacy
(green line), and only lack and loss of efficacy (red line). The “time 0” is
represented by the start of ANA treatment; the “event” corresponds to
treatment withdrawal.
serum ferritin levels (ρ = 0.09, p = 0.34), and physician’s global
assessment (ρ =−0.008, p = 0.94).
At the binary stepwise regression analysis no variables
collected at baseline were found to predict primary inefficacy.
Conversely, the number of swollen joints at baseline accounted
for the only variable capable to predict secondary inefficacy
(p = 0.01, OR = 1.194, C.I. 1.043–1.367), while neither tender
joints nor DAS28-CRP could be included in a predictive model
(p = 0.30 and p = 0.29, respectively).
Binary stepwise regression analysis applied on data collected
at baseline identified skin rash as the only variable negatively
associated with ANA discontinuation due to long-term remission
over time (p = 0.03, OR = 0.224, C.I. 0.058–0.863).
Among AOSD clinical manifestations, fever (p = 0.006),
pharyngodynia (p = 0.02), tender (p = 0.02), and swollen
(p = 0.021) joints were the clinical manifestations significantly
associated with primary inefficacy at the 3-month follow-up visit
FIGURE 3 | Cumulative DRR of Anakinra in patients with AOSD undergoing
their first biologic agent and those previously treated with other biologics.
(or at the last ANA administration). Among laboratory findings,
leukocytosis (p = 0.004) and increased ESR (p = 0.006) observed
at the 3-month assessment were significantly associated with
primary inefficacy, while CRP (p = 0.10) and serum ferritin
(p = 0.14) did not.
DISCUSSION
Different clinical and basic research have uncovered the key-role
of IL-1 in an extended spectrum of immune dysregulatory
conditions, and after showing the dramatic success and safety
profile of IL-1 inhibitors in the treatment of cryopyrin-associated
periodic syndrome, a complex disease spectrum caused by
excessive release of the proinflammatory cytokine IL-1 (Cantarini
et al., 2011), many clinicians have been encouraged to a wider
use of these drugs in other disorders, including AOSD. During
the last decade, ANA has proven to induce a rapid and dramatic
improvement of all clinical and laboratory AOSD manifestations,
resulting in tapering and discontinuation of concomitant therapy
with corticosteroids, NSAIDs, and cDMARDs (Lequerré et al.,
2008; Nordström et al., 2008; Giampietro et al., 2013; Ortiz-
Sanjuán et al., 2015; Colafrancesco et al., 2017). The efficacy of
ANA may also allow a decrease in the frequency of injections
until complete withdrawal in some cases (Kong et al., 2010;
Colafrancesco et al., 2017). However, lack and loss of efficacy
are not rare and require a switch to other treatment approaches,
including different IL-1 blockers or IL-6 inhibition (Giampietro
et al., 2013; Cavalli et al., 2015; Ortiz-Sanjuán et al., 2015; Rossi-
Semerano et al., 2015). Therefore, the present study has been
designed to identify any baseline predictor of different outcomes
to ANA treatment and evaluate the effectiveness of ANA over
time by assessing the long-term DRR with regard to the different
causes which might affect survival.
A remarkable DRR was identified during a 10-year study
period with 30.5% of patients continuing ANA at the 120-month
assessment, when reasons for discontinuation were considered as
a whole. This percentage increased to 39.5% when considering
only lack/loss of efficacy and adverse events, while more than half
of patients continued ANA when the sole lack and loss of efficacy
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FIGURE 4 | Cumulative DRR of Anakinra in patients with AOSD concomitantly administered with cDMARDs and those treated with IL-1 blockade as monotherapy at
the start of ANA treatment (A) and at the last follow-up visit (B).
FIGURE 5 | Cumulative DRR of Anakinra in patients with AOSD in both
systemic and chronic articular type.
were taken into account. Notably, the risk for loss of efficacy was
considerably low with a less than 4% of cumulative risk identified
during the first follow-up year. Likewise, the cumulative risk for
loss of efficacy increased to only 13.5% during a 5-year period
and affected about 1/6 patients during the entire follow-up. As
a whole, these results confirm the excellent efficacy of ANA in
a higher number of AOSD patients during a substantially long
observational period.
In this study the occurrence of adverse events accounts for
a leading reason capable to affect the DRR of ANA. However,
as also highlighted by Colafrancesco et al. (2017), in our cohort
of patients the frequency of adverse events was higher than
that reported in previous studies. This could be related to
different variables including the longer follow-up period and the
relatively low percentage of patients concomitantly treated with
cDMARDs. In this regard, Rossi-Semerano et al. (2015) found
that background cDMARDs treatment was associated with lower
odds of adverse events among patients administered with ANA
because of different indications, most of which were represented
by AOSD and SOJIA. In addition, the high percentage of MAS
cases might be indicative of particular disease severity in our
cohort. To the best of our knowledge, this is the first study
assessing the DRR of ANA in AOSD patients. However, Woerner
et al. (2015) analyzed the DRR of ANA in 51 SOJIA patients
undergoing their first biologic agent and in eight cases treated
with ANA as second or third biologic option. The estimate of
ANA continuation was about 35% at the 100-month assessment
in biologic naïve patients when adverse events, ineffectiveness
of treatment, loss of response, convenience of use, and patient’s
choice were included in the statistical computation. Conversely,
the DRR of ANA was strikingly lower among the eight patients
previously treated with other biologics, running by 33% at
24 months. A further study proposed by Otten et al. (2013)
described a 65% retention of ANA at 12-month follow-up
in patients previously exposed to the tumor necrosis factor-α
inhibitor etanercept. As inferred from Figure 3, our findings
are in line with the results reported by Otten et al. (2013).
Similarly, the long-term DRR of ANA obtained from our AOSD
patients is very similar to that reported by Woerner et al. (2015)
on biologic naïve SOJIA subjects. Nevertheless, the differences
identified in the DRR of ANA between patients undergoing
their first biologic agent and those previously treated with other
biologics are almost unremarkable in our cohort of patients. This
discrepancy could be explained by the higher number of patients
enrolled in our study.
Noteworthy, the DRR of ANA was not affected by the
concomitant use of cDMARDs suggesting that long-term
outcome does not differ between monotherapy and combination
treatment. However, although other studies have shown similar
results (Nigrovic et al., 2011; Giampietro et al., 2013), to date
there is no clear evidence that using concomitant cDMARDs
does not influence ANA efficacy in SOJIA or AOSD patients and
the need to combine ANA with other immunosuppressive drugs
should further be explored.
The stepwise binary regression analysis performed on
demographic, clinical and laboratory data collected at the start of
treatment did not identify any variable capable to anticipate the
lack of ANA efficacy; conversely, the number of swollen joints
at baseline was the only variable capable to predict secondary
inefficacy, while the presence of the typical salmon-like skin
rash represented the sole variable associated with the lack of
ANA withdrawal owing to sustained clinical remission. Figures 6,
7 show joint involvement and maculopapular skin rash in a
patient with AOSD.
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FIGURE 6 | Arthritis involving the right hand in a male patient with AOSD. In
particular, the second and third metacarpophalangeal joints, as well as the
distal interphalangeal joint of the index finger and the proximal interphalangeal
joints of the middle and annular fingers are swollen.
According to published evidences, articular involvement
has been frequently described as less responsive than AOSD
systemic features (Cavalli et al., 2015; Ortiz-Sanjuán et al.,
2015). More in detail, although the frequency of joint symptoms
decreases during ANA treatment, articular involvement
remains more frequent than other AOSD manifestations
(Ortiz-Sanjuán et al., 2015). In addition, articular involvement
seems to resolve slowly (within 1 or 2 years), while joint damage
could also progress (Lequerré et al., 2008; Lahiri and Teng,
2010; Giampietro et al., 2013). A similar experience has been
highlighted also in SOJIA patients: according with Gattorno
et al. (2008), subjects with complete response to ANA showed
a significantly lower number of active joints compared with
patients experiencing incomplete advantage. As a whole, these
data seem to corroborate our results on the predictive value of
the baseline number of swollen joints on a later loss of efficacy.
Noteworthy, the presence of skin rash at the start of ANA
treatment turned out to be a negative predictor of long-term
remission leading to ANA withdrawal. This finding could be
explained by an even higher IL-1 overproduction in AOSD
patients presenting with skin manifestations. In support of this,
the persistence of skin lesions has been found to correlate with
systemic disease activity, onset of complications, and a more
severe prognosis (Fortna et al., 2010; Lee et al., 2012; Yamamoto,
2012; Kikuchi et al., 2014; Sarkar et al., 2014; Cozzi et al., 2016).
FIGURE 7 | Maculopapular skin rash involving the lower limbs in a female
patient suffering from AOSD.
In this regard, a possible role of the innate immune system of the
skin has been suggested in maintaining the degree of systemic
inflammation in AOSD (Ruscitti et al., 2016a), while tissue IL-1
levels and other IL-1 family members have proved to be expressed
largely in the skin of AOSD patients (Chen et al., 2004; Ruscitti
et al., 2016a; Han et al., 2017).
Interestingly, no statistically significant results have been
obtained in relationship with AOSD duration before starting
ANA treatment. Indeed, according with previous experiences on
SOJA patients a shorter time from disease onset to receiving ANA
was significantly associated with a favorable response (Nigrovic
et al., 2011; Pardeo et al., 2015). On this basis, some authors have
speculated about a “window of opportunity” after disease onset
during which an early treatment with IL-1 inhibition might have
the highest advantage (Nigrovic et al., 2011; Vastert et al., 2014).
However, according with our results, disease duration before
starting ANA does not predict any outcome and is not correlated
with treatment duration in adults with AOSD. Furthermore, no
differences were identified in the DRR of ANA on the basis of the
different lines of biologic treatment.
Of note, no predictive values were identified neither for the
baseline number of tender joints nor for the DAS28-CRP, that
is a very useful disease activity score to make an objective,
reproducible and comparable evaluation of arthritis activity.
Also, no significant differences were identified in the DRR of
ANA between AOSD patients suffering from systemic type and
those presenting a chronic articular type, while baseline articular
involvement did not represent a risk factor for primary inefficacy.
On this basis, although the risk for secondary inefficacy increases
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along with the number of swollen joints at the start of treatment,
the presence of arthritis does not affect the short- and long-term
response to ANA. Conversely, both systemic and articular
features persisted at ANA withdrawal in the subset of patients
experiencing lack of efficacy. In particular, fever, pharyngodynia,
tender and swollen joints, leukocytosis and increased ESR proved
to be the significantly more frequent in the case of ANA failure
compared to other patients at the 3-month assessment (or at the
last ANA administration).
When we looked for baseline variables capable to correlate
with treatment duration, no significant findings were identified
among demographic, laboratory or clinimetric data. In particular,
neither the Pouchot score, nor the DAS28-CRP nor the
physician’s global assessment correlated with the treatment
duration. Similarly, no correlations were identified with baseline
serum ferritin levels. These findings are of any importance as both
the Pouchot score and serum ferritin levels have been correlated
with AOSD activity, clinical severity, and prognosis (Efthimiou
et al., 2014; Ruscitti et al., 2016b), but do not seem to anticipate
the response to ANA treatment.
The main limit of this study is represented by its retrospective
nature that prevented to include some interesting quantitative
variables for statistical computation. In particular, white cell
count, liver enzymes levels, ESR and CRP at baseline were
only available as qualitative data (increased/not increased).
Consequently, they could not be correlated with treatment
duration and were computed as binary information in the
stepwise regression analysis. However, all the variables analyzed
showed a very low percentage of missing values (<5%)
in the data set. In addition, this study is based on a
real-life experience and data recorded reflect the everyday
management of a wide number of AOSD patients enrolled
in 18 different Italian tertiary Centers. This is especially
important in reducing recruitment and withdrawal biases, as
no defined criteria are currently applicable for starting or
stopping ANA in AOSD.
CONCLUSION
The present study highlights an excellent long-term DRR of ANA
with no significant differences according with the different line
of biologic treatment, concomitant use of cDMARDs, or type of
AOSD (systemic versus chronic articular). In addition, while no
variables have been found to predict primary inefficacy of ANA,
the risk for a loss of efficacy increases along with the number of
swollen joints at the start of treatment; similarly, the presence of
the typical salmon-like maculopapular skin rash at the start of
ANA is the only clinical manifestation negatively associated with
sustained remission leading to ANA withdrawal over time.
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